Apatinib for Advanced Biliary Carcinoma
This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib 500-750mg qd until progression of disease.
Biliary Tract Neoplasms
DRUG: Apatinib
PFS, progression free survival, from the time signing of ICF until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
OS, overall survival, from the time signing of ICF until the date of death from any cause, assessed up to 48 months
This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib 500-750mg qd until progression of disease.